Found 24 results
Filters: Keyword is Antineoplastic Agents  [Clear All Filters]
Journal Article
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90., Moulick, Kamalika, Ahn James H., Zong Hongliang, Rodina Anna, Cerchietti Leandro, DaGama Erica M. Gomes, Caldas-Lopes Eloisi, Beebe Kristin, Perna Fabiana, Hatzi Katerina, et al. , Nat Chem Biol, 2011 Sep 25, Volume 7, Issue 11, p.818-26, (2011)
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia., Fiskus, Warren, Saba Nakhle, Shen Min, Ghias Mondana, Liu Jinyun, Gupta Soumyasri Das, Chauhan Lata, Rao Rekha, Gunewardena Sumedha, Schorno Kevin, et al. , Cancer Res, 2014 May 01, Volume 74, Issue 9, p.2520-32, (2014)
Derepression in the desert: the third workshop on clinical translation of epigenetics in cancer therapeutics., Zelent, Arthur, Petrie Kevin, Boix-Chornet Manuel, Melnick Ari M., Waxman Samuel, and Gore Steven D. , Cancer Res, 2008 Jul 01, Volume 68, Issue 13, p.4967-70, (2008)
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling., Guryanova, Olga A., Shank Kaitlyn, Spitzer Barbara, Luciani Luisa, Koche Richard P., Garrett-Bakelman Francine E., Ganzel Chezi, Durham Benjamin H., Mohanty Abhinita, Hoermann Gregor, et al. , Nat Med, 2016 Dec, Volume 22, Issue 12, p.1488-1495, (2016)
Emerging epigenetic-modulating therapies in lymphoma., Sermer, David, Pasqualucci Laura, Wendel Hans-Guido, Melnick Ari, and Younes Anas , Nat Rev Clin Oncol, 2019 Aug, Volume 16, Issue 8, p.494-507, (2019)
Enhancer of zeste homolog 2 (EZH2) inhibitors., Gulati, Nitya, Béguelin Wendy, and Giulino-Roth Lisa , Leuk Lymphoma, 2018 Jul, Volume 59, Issue 7, p.1574-1585, (2018)
The epichaperome is an integrated chaperome network that facilitates tumour survival., Rodina, Anna, Wang Tai, Yan Pengrong, Gomes Erica DaGama, Dunphy Mark P. S., Pillarsetty Nagavarakishore, Koren John, Gerecitano John F., Taldone Tony, Zong Hongliang, et al. , Nature, 2016 Oct 20, Volume 538, Issue 7625, p.397-401, (2016)
Epigenetic Mechanisms in Leukemias and Lymphomas., Duy, Cihangir, Béguelin Wendy, and Melnick Ari , Cold Spring Harb Perspect Med, 2020 Dec 01, Volume 10, Issue 12, (2020)
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia., Shojaee, Seyedmehdi, Caeser Rebecca, Buchner Maike, Park Eugene, Swaminathan Srividya, Hurtz Christian, Geng Huimin, Chan Lai N., Klemm Lars, Hofmann Wolf-Karsten, et al. , Cancer Cell, 2015 Jul 13, Volume 28, Issue 1, p.114-28, (2015)
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models., Caldas-Lopes, Eloisi, Cerchietti Leandro, Ahn James H., Clement Cristina C., Robles Ana I., Rodina Anna, Moulick Kamalika, Taldone Tony, Gozman Alexander, Guo Yunke, et al. , Proc Natl Acad Sci U S A, 2009 May 19, Volume 106, Issue 20, p.8368-73, (2009)
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species., Zong, Hongliang, Gozman Alexander, Caldas-Lopes Eloisi, Taldone Tony, Sturgill Eric, Brennan Sarah, Ochiana Stefan O., Gomes-DaGama Erica M., Sen Siddhartha, Rodina Anna, et al. , Cell Rep, 2015 Dec 15, Volume 13, Issue 10, p.2159-73, (2015)
Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia., Buchner, Maike, Park Eugene, Geng Huimin, Klemm Lars, Flach Johanna, Passegué Emmanuelle, Schjerven Hilde, Melnick Ari, Paietta Elisabeth, Kopanja Dragana, et al. , Nat Commun, 2015 Mar 10, Volume 6, p.6471, (2015)
Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design., Cheng, Huimin, Linhares Brian M., Yu Wenbo, Cardenas Mariano G., Ai Yong, Jiang Wenjuan, Winkler Alyssa, Cohen Sandra, Melnick Ari, MacKerell Alexander, et al. , J Med Chem, 2018 Sep 13, Volume 61, Issue 17, p.7573-7588, (2018)
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells., Tian, Ye F., Ahn Haelee, Schneider Rebecca S., Yang Shao Ning, Roman-Gonzalez Lidia, Melnick Ari M., Cerchietti Leandro, and Singh Ankur , Biomaterials, 2015 Dec, Volume 73, p.110-9, (2015)
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia., Brown, Fiona C., Still Eric, Koche Richard P., Yim Christina Y., Takao Sumiko, Cifani Paolo, Reed Casie, Gunasekera Shehana, Ficarro Scott B., Romanienko Peter, et al. , Cancer Discov, 2018 Apr, Volume 8, Issue 4, p.478-497, (2018)
Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia., Shih, Alan H., Jiang Yanwen, Meydan Cem, Shank Kaitlyn, Pandey Suveg, Barreyro Laura, Antony-Debre Ileana, Viale Agnes, Socci Nicholas, Sun Yongming, et al. , Cancer Cell, 2015 Apr 13, Volume 27, Issue 4, p.502-15, (2015)
Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis., Li, Meng, Chiang Ying-Ling, Lyssiotis Costas A., Teater Matthew R., Hong Jun Young, Shen Hao, Wang Ling, Hu Jing, Jing Hui, Chen Zhengming, et al. , Cancer Cell, 2019 Jun 10, Volume 35, Issue 6, p.916-931.e9, (2019)
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo., Cerchietti, Leandro C., Yang Shao Ning, Shaknovich Rita, Hatzi Katerina, Polo Jose M., Chadburn Amy, Dowdy Steven F., and Melnick Ari , Blood, 2009 Apr 09, Volume 113, Issue 15, p.3397-405, (2009)
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma., Cardenas, Mariano G., Yu Wenbo, Béguelin Wendy, Teater Matthew R., Geng Huimin, Goldstein Rebecca L., Oswald Erin, Hatzi Katerina, Yang Shao-Ning, Cohen Joanna, et al. , J Clin Invest, 2016 Sep 01, Volume 126, Issue 9, p.3351-62, (2016)
Sequential transcription factor targeting for diffuse large B-cell lymphomas., Cerchietti, Leandro C., Polo Jose M., Da Silva Gustavo F., Farinha Pedro, Shaknovich Rita, Gascoyne Randy D., Dowdy Steven F., and Melnick Ari , Cancer Res, 2008 May 01, Volume 68, Issue 9, p.3361-9, (2008)
Specific peptides for the therapeutic targeting of oncogenes., Prive, Gilbert G., and Melnick Ari , Curr Opin Genet Dev, 2006 Feb, Volume 16, Issue 1, p.71-7, (2006)
SYK inhibition and response prediction in diffuse large B-cell lymphoma., Cheng, Shuhua, Coffey Greg, X Zhang Hannah, Shaknovich Rita, Song Zibo, Lu Pin, Pandey Anjali, Melnick Ari M., Sinha Uma, and Y Wang Lynn , Blood, 2011 Dec 08, Volume 118, Issue 24, p.6342-52, (2011)
Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?, Cerchietti, Leandro, and Melnick Ari , Expert Rev Hematol, 2013 Aug, Volume 6, Issue 4, p.343-5, (2013)
Targeting lymphomas through MALT1 inhibition., Fontan, Lorena, and Melnick Ari , Oncotarget, 2012 Dec, Volume 3, Issue 12, p.1493-4, (2012)